Jasper Therapeutics (NASDAQ:JSPR) Now Covered by Analysts at Stifel Nicolaus

Stifel Nicolaus began coverage on shares of Jasper Therapeutics (NASDAQ:JSPR - Get Free Report) in a research note issued on Thursday, Marketbeat reports. The firm set a "buy" rating and a $86.00 price target on the stock. Stifel Nicolaus' price objective suggests a potential upside of 290.73% from the stock's previous close.

Other research analysts have also recently issued research reports about the company. TD Cowen began coverage on Jasper Therapeutics in a research note on Monday, March 18th. They issued an "outperform" rating for the company. Evercore ISI assumed coverage on Jasper Therapeutics in a research note on Wednesday, April 3rd. They set an "outperform" rating and a $65.00 price objective for the company. Royal Bank of Canada assumed coverage on Jasper Therapeutics in a research note on Thursday, March 28th. They set an "outperform" rating and a $70.00 price objective for the company. Oppenheimer reiterated an "outperform" rating and set a $80.00 price objective on shares of Jasper Therapeutics in a research note on Thursday, March 7th. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Jasper Therapeutics in a research note on Tuesday, June 18th. Ten investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of "Buy" and an average target price of $67.00.

Jasper Therapeutics Stock Performance

Shares of JSPR traded up $1.03 on Thursday, reaching $22.01. The stock had a trading volume of 158,855 shares, compared to its average volume of 108,644. The firm has a market capitalization of $331.47 million, a price-to-earnings ratio of -3.91 and a beta of 2.24. The company has a 50-day simple moving average of $23.10 and a 200-day simple moving average of $19.20. Jasper Therapeutics has a 12-month low of $4.00 and a 12-month high of $31.01.

Jasper Therapeutics (NASDAQ:JSPR - Get Free Report) last released its earnings results on Tuesday, May 14th. The company reported ($1.03) EPS for the quarter, beating analysts' consensus estimates of ($1.26) by $0.23. On average, analysts expect that Jasper Therapeutics will post -4.36 EPS for the current fiscal year.

Institutional Trading of Jasper Therapeutics

Several large investors have recently modified their holdings of JSPR. Ieq Capital LLC bought a new stake in shares of Jasper Therapeutics in the fourth quarter worth $43,000. Monaco Asset Management SAM bought a new stake in shares of Jasper Therapeutics in the fourth quarter worth $197,000. Virtu Financial LLC bought a new stake in shares of Jasper Therapeutics in the first quarter worth $306,000. Fernwood Investment Management LLC grew its holdings in shares of Jasper Therapeutics by 8.8% in the fourth quarter. Fernwood Investment Management LLC now owns 494,706 shares of the company's stock worth $390,000 after acquiring an additional 40,000 shares during the period. Finally, Concurrent Investment Advisors LLC bought a new stake in shares of Jasper Therapeutics in the first quarter worth $599,000. Institutional investors own 79.85% of the company's stock.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.